The US Food and Drug Administration (FDA) today (Aug. 21) approved the first vaccine for respiratory syncytial virus (RSV) for pregnant women, which is designed to protect newborns from the infection. The shot becomes the second RSV vaccine, and third new intervention against the disease this year. In May, the FDA approved the Abrysvo vaccine for preventing RSV in people 60 years and older.